Puma Biotechnology Inc (PBYI) Shares are Down -1.51%

Puma Biotechnology Inc (PBYI) has risen sharply, recording gains of 16.65% in the past 4 weeks. However, the stock has corrected -1.51% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 17.28% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 6.73% and the 50-Day Moving Average is 21.96%.The 200 Day SMA reached 51.83%


Puma Biotechnology Inc (NYSE:PBYI): After opening at $63.07, the stock dipped to an intraday low of $60.25 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $67.38 and the buying power remained strong till the end. The stock closed at $67.05 for the day, a gain of 1.50% for the day session. The total traded volume was 1,789,261. The stocks close on the previous trading day was $67.05.

Puma Biotechnology Inc (PBYI) : Average target price received by Puma Biotechnology Inc (PBYI) is $85.5 with an expected standard deviation of $3.54. The most aggressive target on the stock is $88, whereas the most downbeat target is $83. 2 financial analysts are currently covering the stock.

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *